GSK1838705A

Bezeichnung:GSK1838705A

CAS-Nr1116235-97-2

Englisch Name:GSK1838705A

CBNumberCB72605356

SummenformelC27H29FN8O3

Molgewicht532.57

MOL-Datei1116235-97-2.mol

GSK1838705A physikalisch-chemischer Eigenschaften

Dichte	1.399
storage temp.	-20°C
Löslichkeit	DMSO: soluble20mg/mL, clear
Aggregatzustand	powder
pka	13.27±0.50(Predicted)
Farbe	white to light brown

Sicherheit

WGK Germany

Gefahreninformationscode (GHS)

GSK1838705A Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden
GSK 1838705 is a potent IR and IGF1R inhibitor; also inhibits anaplastic lymphoma kinase (ALK).
Definition
ChEBI: 2-[[2-[[1-[2-(dimethylamino)-1-oxoethyl]-5-methoxy-2,3-dihydroindol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide is an organooxygen compound and an organonitrogen compound. It is functionally related to an alpha-amino acid.
Biologische Aktivität
gsk1838705a is a small-molecule kinase inhibitor that inhibits igf-ir and the insulin receptor with ic50s of 2.0 and 1.6 nmol/l, respectively.igf-1r is a transmembrane receptor which is activated by insulin-like growth factor 1 and by a related hormone igf-2. this protein plays important role in the regulation of development. the insulin receptor is also a transmembrane receptor that is activated by insulin, igf-1 and igf2. this receptor is involved in insulin signaling pathway and plays an essential role in the regulation of glucose homeostasis.gsk1838705a obstructs the in vitro expansion of cell lines got from strong and hematologic malignancies, including numerous myeloma and ewing's sarcoma, and hinders the development of human tumor xenografts in vivo. in spite of the inhibitory impact of gsk1838705a on insulin receptor, insignificant effects on glucose homeostasis were seen at efficacious dosages. gsk1838705a represses the anaplastic lymphoma kinase (alk), which drives the distorted development of anaplastic substantial cell lymphomas, some neuroblastomas, and a subset of non–small cell lung growths.gsk1838705a restrains alk, with an ic50 value of 0.5 nm, furthermore, causes complete relapse of alk-ward tumors in vivo at very-endured measurements. gsk1838705a arrives for a promising antitumor agent for helpful use in human growth.
Lager
Store at -20°C
Einzelnachweise
[1]. sabbatini p, et al. gsk1838705a inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. mol cancer ther. 2009 oct;8(10):2811-20.

GSK1838705A Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Send Inquriy